Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed the day trading at $1.97 down -2.96% from the previous closing price of $2.03. On the day, 1867456 shares were traded.
Ratios:
For a better understanding of LXRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.58 and its Current Ratio is at 5.60. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 1.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 07, 2023, initiated with a Hold rating and assigned the stock a target price of $3.
On August 12, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.
JP Morgan Upgraded its Underweight to Neutral on January 29, 2021, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 16 ’23 when COATS LONNEL bought 90,000 shares for $1.05 per share. The transaction valued at 94,797 led to the insider holds 914,359 shares of the business.
COATS LONNEL bought 10,000 shares of LXRX for $10,100 on Nov 10 ’23. The Chief Executive Officer now owns 824,359 shares after completing the transaction at $1.01 per share. On Oct 12 ’23, another insider, DEBBANE RAYMOND, who serves as the Director of the company, bought 148,820 shares for $1.03 each. As a result, the insider paid 153,805 and bolstered with 1,340,847 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 400.90 while its Price-to-Book (P/B) ratio in mrq is 5.18.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $3.79, while it has fallen to a 52-week low of $0.92.
Shares Statistics:
A total of 244.92M shares are outstanding, with a floating share count of 239.55M. Insiders hold about 2.72% of the company’s shares, while institutions hold 26.65% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from Lexicon Pharmaceuticals, Inc. analysts. The consensus estimate for the next quarter is $8.41, with high estimates of $3.31 and low estimates of $16.85.
Analysts are recommending an EPS of between $Technology and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
